Paratek Pharmaceuticals Inc
F:N4CN
Paratek Pharmaceuticals Inc
Research & Development
Paratek Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Paratek Pharmaceuticals Inc
F:N4CN
|
Research & Development
-$38.8m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-16%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Paratek Pharmaceuticals Inc
Glance View
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The firm's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.
See Also
What is Paratek Pharmaceuticals Inc's Research & Development?
Research & Development
-38.8m
USD
Based on the financial report for Jun 30, 2023, Paratek Pharmaceuticals Inc's Research & Development amounts to -38.8m USD.
What is Paratek Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-16%
Over the last year, the Research & Development growth was -16%. The average annual Research & Development growth rates for Paratek Pharmaceuticals Inc have been -11% over the past three years , 7% over the past five years , and -16% over the past ten years .
